NCT05976893View on ClinicalTrials.gov

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

620

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

ASCVDAtherosclerotic Cardiovascular DiseaseProprotein Convertase Subtilisin/Kexin Type 9 InhibitorCancer

Interventions

DRUG

Evolocumab

Evolocuma:420 mg every 4 weeks

DRUG

Statin

The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).

All Listed Sponsors

collaborator

Xinjiang Medical University

OTHER

lead

Xiang Xie

OTHER